Skip to main content
SpringerLink
Log in

Management of Acute and Chronic Gouty Arthritis

Present State-of-the-Art

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

There are three stages in the management of gout: (i) treating the acute attack; (ii) lowering excess stores of uric acid to prevent flares of gouty arthritis and to prevent tissue deposition of urate; and (iii) providing prophylaxis to prevent acute flares. It is important to distinguish between therapy to reduce acute inflammation in acute gout and therapy to manage hyperuricaemia in patients with chronic gouty arthritis.

During the acute gouty attack nonpharmacological treatments such as topical ice and rest of the inflamed joint are useful. NSAIDs are the preferred treatment in acute gout. The most important determinant of therapeutic success is not which NSAID is chosen, but rather how soon NSAID therapy is initiated. Other treatments include oral and intravenous colchicine, intra-articular and systemic corticosteroids, and intramuscular corticotropin.

Optimal treatment of chronic gout requires long-standing reduction in serum uric acid. The urate-lowering drugs used to treat chronic gout are the uricosuric drugs, the uricostatic drugs, which are xanthine oxidase inhibitors, and the uricolytic drugs. Xanthine oxidase inhibitors such as allopurinol, oxipurinol and febuxastat should be used as first-line treatment in patients with renal calculi, renal insufficiency, concomitant diuretic therapy and ciclosporin (cyclosporine) therapy, and urate overproduction. Uricosuric drugs include probenecid, benzbromarone, micronised fenofibrate and losartan. They are the urate-lowering drugs of choice in allopurinol-allergic patients and underexcretors with normal renal function and no history of urolithiasis. The use of recombinant urate oxidase in patients with chronic gout is limited by the need for parenteral administration, the potential antigenicity and production of anti-urate oxidase antibodies, and declining efficacy.

The effectiveness of colchicine prophylaxis as an isolated therapy is still to be confirmed by placebo-controlled trials. Another issue is prophylaxis with NSAIDs. There are no comparative studies with colchicine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Table IV

Similar content being viewed by others

Notes

  1. The use of trade names is for product identification purposes only and does not imply endorsement.

References

  1. Campion EW, Glynn RJ, DeLabry LO. Asymptomatic hyperuricemia: risks and consequences in the Normative Aging Study. Am J Med 1987; 82: 421–6

    Article  PubMed  CAS  Google Scholar 

  2. Yu TF, Gutman AB. Uric acid nephrolithiasis in gout: predisposing factors. Ann Intern Med 1967; 67: 1133–48

    PubMed  CAS  Google Scholar 

  3. Wortmann RL. Effective management of gout: an analogy. Am J Med 1998 Dec; 105: 513–4

    Article  PubMed  CAS  Google Scholar 

  4. Grahame R, Scott JT. Clinical survey of 354 patients with gout. Ann Rheum Dis 1970; 29: 461–8

    Article  PubMed  CAS  Google Scholar 

  5. Weede RP. Poison in the pot: the legacy of lead. Carbondale (IL): Southern Illinois University Press, 1984: 83

    Google Scholar 

  6. Comrie JD, editor. Selected works of Thomas Syndenham MD with a short biography and explanatory notes. London: Bale J, Sons and Danielson, 1922

    Google Scholar 

  7. Bacethge BA, Work J, Landreneau MD, et al. Tophaceous gout in patients with renal transplantation treated with cyclosporine A. J Rheumatol 1993; 20: 718–200

    Google Scholar 

  8. Wernick R, Winkler C, Campbell S. Tophi as the initial manifestation of gout: report of six cases and review of the literature. Arch Intern Med 1992; 152: 873–6

    Article  PubMed  CAS  Google Scholar 

  9. Roubenoff R, Klag MJ, Mead LA, et al. Incidence and risk factors for gout in white men. JAMA 1991; 266: 3004–7

    Article  PubMed  CAS  Google Scholar 

  10. Lawrence RC, Hochberg MC, Kelsey JL, et al. Estimates of the prevalence of selected arthritis and Musculoskeletal disease in the United States. J Rheumatol 1989; 16: 427–41

    PubMed  CAS  Google Scholar 

  11. Mikkelson WH, Dodge HJ, Valkenberg H. The distribution of plasma uric acid values in a population unselected as to gout and hyperuricemia. Am J Med 1965; 39: 242–51

    Article  Google Scholar 

  12. O’Sullivan JB. Gout in a New England town: a prevalence study in Sudbury Massachusetts. Ann Rheum Dis 1972; 31: 166–9

    Article  PubMed  Google Scholar 

  13. Perkins P, Jones AC. Gout. Ann Rheum Dis 1999; 58: 611–61

    Article  PubMed  CAS  Google Scholar 

  14. Clive DM. Renal transplant-associated hyperuricemia and gout. J Am Soc Nephrol 2000; 11: 974–9

    PubMed  CAS  Google Scholar 

  15. Adams PF, Hendershot GE, Marano MA. Current estimates from the National Health Interview Survey, 1996. Series 10. No. 200 [online]. Available from URL: http://www.cdc.gov/nchs/data/series/sr_l0/10_200_l.pdf [Accessed 2003 Jan 5]

  16. Klemp P, Shelley A, Stansfield SA, et al. Gout is on the increase in New Zealand. Ann Rheum Dis 1997; 56: 22–6

    Article  PubMed  CAS  Google Scholar 

  17. Healy LA, Skeith MD, Decker JL, et al. Hyperuricemia in Filipinos: interaction of heredity and environment. Am J Hum Genet 1967; 19: 81–5

    Google Scholar 

  18. Schlesinger N, Baker DG, Beutler AM, et al. Acute gouty arthritis is seasonal. J Rheumatol 1998; 25: 342–4

    PubMed  CAS  Google Scholar 

  19. Boss GR, Seegmiller JE. Hyperuricemia and gout: classification, complications and management. N Engl J Med 1979 Jun 28; 300(26): 1459–68

    Article  PubMed  CAS  Google Scholar 

  20. Hall AP, Berry PE, Dawber TR, et al. Epidemiology of gout and hyperuricemia: a long-term population study. Am J Med 1967; 42: 27–37

    Article  PubMed  CAS  Google Scholar 

  21. Perez-Ruiz F, Calabozo M, Erauskin GG, et al. Renal underexcretion of uric acid is present in patients with apparent high urinary uric acid output. Arthritis Rheum 2002; 47(6): 610–3

    Article  PubMed  CAS  Google Scholar 

  22. McCarty DJ, Hollander JL. Identification of urate crystals in gouty synovial fluid. Ann Intern Med 1961; 54: 452–60

    PubMed  CAS  Google Scholar 

  23. Lally EV, Zimmerman B, Ho G, et al. Urate mediated inflammation in nodal arthritis: clinical and roentgenographic correlations. Arthritis Rheum 1989; 32: 86–90

    Article  PubMed  CAS  Google Scholar 

  24. Reginato AJ, Schumacher Jr HR. Crystal associated arthropathies. Clin Geriatr Med 1988; 4: 295–322

    PubMed  CAS  Google Scholar 

  25. Weinberger A, Schumacher HR, Agudelo CA. Urate crystals in asymptomatic metatarsophalangeal joints. Ann Intern Med 1979; 92: 56–7

    Google Scholar 

  26. Bomalaski JS, Lluberas G, Schumacher Jr HR. Monosodium urate crystals in the knee joints of patients with asymptomatic nontophaceous gout. Arthritis Rheum 1986; 29: 1480–4

    Article  PubMed  CAS  Google Scholar 

  27. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900

    Article  PubMed  CAS  Google Scholar 

  28. Schlesinger N, Baker DG, Schumacher Jr HR. Gout: how well have diagnostic tests and therapies been evaluated? Curr Opin Orthop 2000; 11: 71–6

    Article  Google Scholar 

  29. Schlesinger N, Baker DG, Schumacher Jr HR. Gout: can management be improved? Curr Opin Rheumatol 2001; 13(3): 240–4

    Article  PubMed  CAS  Google Scholar 

  30. Lin KC, Lin HY, Chou P. Community based epidemiological study on hyperuricemia and gout in Kin-Hu, Kimmen. J Rheumatol 2000; 27: 1045–50

    PubMed  CAS  Google Scholar 

  31. Lin KC, Lin HY, Chou P. The interaction between SUA level and other risk factors on the development of gout among asymptomatic hyperuricemic men in a prospective study. J Rheumatol 2000; 27: 1501–5

    PubMed  CAS  Google Scholar 

  32. Nicholas A, Scott JT. Effect of weight loss on plasma and urinary levels of uric acid. Lancet 1972; II: 1223–4

    Google Scholar 

  33. Fam AG. Gout, diet, and the insulin resistance syndrome. J Rheumatol 2002; 29: 1350–5

    PubMed  CAS  Google Scholar 

  34. Dessein PH, Shipton AE, Stanwix AE, et al. Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum and lipoprotein levels in gout: a pilot study. Ann Rheum Dis 2000; 59: 539–43

    Article  PubMed  CAS  Google Scholar 

  35. Sharpe CR. A case controlled, study of alcohol consumption and drinking behaviour in patients with acute gout. CMAJ 1984; 131: 563–7

    CAS  Google Scholar 

  36. Agudelo CA, Schumacher Jr HR, Phelps P. Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis Rheum 1972; 15: 609–16

    Article  PubMed  CAS  Google Scholar 

  37. Schumacher Jr HR. Crystal induced arthritis: an overview. Am J Med 1996; 100 Suppl. 2A: 46–52

    Article  Google Scholar 

  38. Schlesinger N, Baker DG, Beutler AM, et al. Local ice therapy during bouts of acute gouty arthritis. J Rheumatol 2002; 29: 331–4

    PubMed  Google Scholar 

  39. Dorwart BB, Hansell JR, Schumacher Jr HR. Effects of cold and heat on urate-induced synovitis in dog. Arthritis Rheum 1974; 17: 563–71

    Article  PubMed  CAS  Google Scholar 

  40. Pittman JR, Bross MH. Prognosis and management of gout. Am Fam Physician 1999; 59: 1799–806

    PubMed  CAS  Google Scholar 

  41. Carew M, Roberts K. Care of the patient with gout. Geriatr Nurs 2000; 20: 156–7

    Google Scholar 

  42. Porter R, Rousseau GS, editors. Gout: the patrician malady. New Haven (CT): Yale University Press, 1998

    Google Scholar 

  43. Singer C. A history of scientific ideas. New York: Barnes and Noble Books, 1996

    Google Scholar 

  44. Peletier PS, Caventon J. [Title unknown]. Ann Chim Phys 1820; 14: 69

    Google Scholar 

  45. Corrodi H, Hardegger E. Die Konfiguration des Colchicins und verwandter Verbindungen. Helv Chem Acta 1955; 38: 2030–3

    Article  CAS  Google Scholar 

  46. Katzung BG, editor. Basic and clinical pharmacology. 6th ed. Norwalk (CT): Appleton and Lange, 1995: 536–59

    Google Scholar 

  47. Levy M, Spino M, Read SE. Colchicine: a state-of-the-art review. Pharmacotherapy 1991; 11: 196–211

    PubMed  CAS  Google Scholar 

  48. Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Aust N Z J Med 1987; 17: 301–4

    Article  PubMed  CAS  Google Scholar 

  49. Paulus HE, Schlosstein LH, Godfrey RC, et al. Prophylactic colchicine therapy in intercritical gout. Arthritis Rheum 1974; 17: 609–14

    Article  PubMed  CAS  Google Scholar 

  50. British National Formulary 48. London: British Medical Association, Royal Pharmaceutical Society of Great Britain, 2004 [online]. Available from URL: http://www.bnf.org/bnf/bnf/48/openat/5311.htm?q=%22colchicine%22 [Accessed 2004 Sep27]

  51. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003; 327: 1275–6

    Article  PubMed  Google Scholar 

  52. Wallace SL, Singer JZ. Review: systemic toxicity associated with the intravenous administration of colchicine: guidelines for use. J Rheumatol 1988; 15: 495–9

    PubMed  CAS  Google Scholar 

  53. Guazzo E. Use of intravenous colchicine for podagra [letter]. Am Fam Physician 1999; 60: 2504–5

    PubMed  CAS  Google Scholar 

  54. Stephan WH. Use of intravenous colchicine in patients with acute gout [letter]. Am Fam Physician 2000; 61: 2343–4

    PubMed  CAS  Google Scholar 

  55. Evans IT, Wheeler MT, Small RE, et al. A comprehensive investigation of inpatient colchicine use shows more education is needed. J Rheumatol 1996; 23: 143–8

    PubMed  CAS  Google Scholar 

  56. Allison MC, Howatson AG, Torrance CJ, et al. Gastrointestinal damage associated with the use of nonsteroidal anti-inflammatory drugs. N Engl J Med 1992; 327: 749–54

    Article  PubMed  CAS  Google Scholar 

  57. Sandier DP, Burr FR, Weinberg CR. Nonsteroidal anti-inflammatory drugs and the risk for chronic renal disease. Ann Intern Med 1991; 115: 165–72

    Google Scholar 

  58. Kelly W, Wortmann RL. Crystal-associated synovitis: gout and hyperuricemia. In: Kelly W, editor. Textbook of rheumatology. 4th ed. Philadelphia (PA): Saunders, 1993: 1340–51

    Google Scholar 

  59. Smyth CJ, Percy JS. Comparison of indomethacin and phenylbutazone in acute gout. Ann Rheum Dis 1973; 32(4): 351–3

    Article  PubMed  CAS  Google Scholar 

  60. Ruosti A, Vainio U. Treatment of acute gouty arthritis with proquazone and indomethacin: a comparative double-blind trial. Scand J Rheumatol Suppl 1978; 21: 15–7

    Google Scholar 

  61. Altaian RD, Honig S, Levin JM, et al. Ketoprofen versus indomethacin in patients with acute gouty arthritis: a multicenter, double blind comparative study. J Rheumatol 1988; 15: 1422–6

    Google Scholar 

  62. Weiner GI, White SR, Weitzner RI, et al. Double blind study of phenoprofen versus phenylbutazone in acute gouty arthritis. Arthritis Rheum 1979; 22: 425–6

    Article  PubMed  CAS  Google Scholar 

  63. Shrestha M, Morgan DL, Moreden JM, et al. Randomized double-blind comparison of the analgesic efficacy of intramuscular ketorolac and oral indomethacin in the treatment of acute gouty arthritis. Ann Emerg Med 1995; 26: 682–6

    Article  PubMed  CAS  Google Scholar 

  64. Maccagno A, Di Giorgio E, Romanowicz A. Effectiveness of etodolac (Lodine) compared with naproxen in patients with acute gout. Curr Med Res Opin 1991; 12: 423–9

    Article  PubMed  CAS  Google Scholar 

  65. Schumacher HR, Boice J, Dahikh DI, et al. Randomized double blind trial of etoricoxib and indomethacin in treatment of acute gouty arthritis. BMJ 2002; 324: 1488–92

    Article  PubMed  CAS  Google Scholar 

  66. Gordon GV, Schumacher Jr HR. Management of gout. Am Fam Physician 1969; 10: 62–6

    Google Scholar 

  67. Gray RG, Tenenbaum J, Gottlieb NL. Local corticosteroid injection treatment in rheumatic disorders. Semin Arthritis Rheum 1979; 10: 231–54

    Article  Google Scholar 

  68. Fernandez C, Noguera R, Gonzalez JA, et al. Treatment of acute attacks of gout with small doses of intraarticular triamcinolone acetonide. J Rheumatol 1999; 26: 2285–6

    PubMed  CAS  Google Scholar 

  69. Groff GD, Franck WA, Raddatz DA. Systemic steroid therapy for acute gout: a clinical trial and review of the literature. Semin Arthritis Rheum 1990; 19: 329–36

    Article  PubMed  CAS  Google Scholar 

  70. Alloway JA, Moriarty MJ, Hoogland YT, et al. Comparison of triamcinolone acetonide with indomethacin in the treatment of acute gouty arthritis. J Rheumatol 1993; 20: 111–3

    PubMed  CAS  Google Scholar 

  71. Getting SJ, Christian HC, Flower RJ, et al. Activation of melanocortin type 3 receptor as a molecular mechanism for adrenocorticotropic hormone efficacy in gouty arthritis. Arthritis Rheum 2002 Oct; 46(10): 2765–75

    Article  PubMed  CAS  Google Scholar 

  72. Ritter J, Kerr LD, Valeriano-Marcet J, et al. ACTH revisited: effective treatment for acute crystal induced synovitis in patients with multiple medical problems. J Rheumatol 1994; 21: 696–9

    PubMed  CAS  Google Scholar 

  73. Axelrod D, Preston S. Comparison of parenteral adrenocorticotropic hormone with oral indomethacin in the treatment of acute gout. Arthritis Rheum 1988; 31: 803–5

    Article  PubMed  CAS  Google Scholar 

  74. Siegel LB, Alloway JA, Nashel DJ. Comparison of adrenocorticotropic hormone and triamcinolone acetonide in the treatment of gouty arthritis. J Rheumatol 1994; 21: 1325–7

    PubMed  CAS  Google Scholar 

  75. Li-Yu J, Clayburne G, Sieck M, et al. Treatment of chronic gout: can we determine when stores are depleted enough to prevent attacks of gout? J Rheumatol 2001; 28: 577–80

    PubMed  CAS  Google Scholar 

  76. Gutman AB. Gout. In: Beeson PB, McDermott W, editors. Textbook of medicine. 12th ed. Philadelphia (PA): WB Saunders, 1958: 895

    Google Scholar 

  77. Fam AG. Should patients with interval gout be treated with urate lowering drugs? J Rheumatol 1995; 22: 1621–3

    PubMed  CAS  Google Scholar 

  78. Emmerson BT. The management of gout. N Engl J Med 1996; 334: 455–551

    Google Scholar 

  79. Ferraz MB. An evidence based appraisal of the management of tophaceous interval gout. J Rheumatol 1995; 22: 1618–20

    PubMed  CAS  Google Scholar 

  80. Perez-Ruiz F, Alonso-Ruiz A, Calaabozo M, et al. Efficacy of allopurinol and benzbromarone for the control of hyperuricemia: a pathogenic approach to the treatment of primary chronic gout. Ann Rheum Dis 1998; 57(9): 545–9

    Article  PubMed  CAS  Google Scholar 

  81. Hepburn AL, Kaye SA, Feber MD. Fenofibrate is a new treatment of hyperuricemia and gout? Ann Rheum Dis 2001; 60: 984–6

    Article  PubMed  CAS  Google Scholar 

  82. Shahinfar S, Simpson RL, Carides AD, et al. Safety of losartan in hypertensive patients with hyperuricemia. Kidney Int 1999; 56: 1879–85

    Article  PubMed  CAS  Google Scholar 

  83. Schumacher Jr HR, Moreno-Alvarez JM. Clued to common crystal induced arthropathies. Intern Med 1993; 14: 35–47

    Google Scholar 

  84. Singer JZ, Wallace SL. The allopurinol hypersensitivity syndrome: unnecessary morbidity and mortality. Arthritis Rheum 1986; 29: 82–7

    Article  PubMed  CAS  Google Scholar 

  85. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76(1): 47–56

    Article  PubMed  CAS  Google Scholar 

  86. Levinson DJ, Becker MA. Clinical gout and the pathogenesis of hyperuricemia. In: McCarty DJ, Koopman WJ, editors. Arthritis and allied conditions. 12th ed. Philadelphia (PA): Lea and Febriger 1993: 1773–818

    Google Scholar 

  87. Bull PW, Scott JT. Intermittent control of hyperuricemia in the treatment of gout. J Rheumatol 1989; 16: 1246–8

    PubMed  CAS  Google Scholar 

  88. Osada Y, Tsuchimoto M, Fukushima H, et al. Hypouricemic effect of the novel xanthine oxidase inhibitor, febuxostat, in rodents. Eur J Pharmacol 1993; 241: 183–8

    Article  PubMed  CAS  Google Scholar 

  89. Komoriya K, Osada Y, Hasegawa M, et al. Hypouricemic effect of allopurinol and the novel xanthine oxidase inhibitor febuxostat in chimpanzees. Eur J Pharmacol 1993; 250: 455–60

    Article  PubMed  CAS  Google Scholar 

  90. Swan S, Khosraven R, Mayer M, et al. Effect of renal impairment on pharmacokinetics, pharmacodynamics and safety of febuxostat (TMX-67), a novel non-purine selective inhibitor of xanthine oxidase [abstract]. Arthritis Rheum 2003; 48 Suppl. 9:529

    Google Scholar 

  91. Joseph-Ridge N. Phase II, dose-response, safety and efficacy clinical trial of a new oral xanthine oxidase inhibitor TMX-67 (febuxostat) in subjects with gout [abstract]. Arthritis Rheum 2002; 46 Suppl. 9: 289

    Google Scholar 

  92. Bellamy N, Gilbert JR, Brooks PM, et al. A survey of current prescribing practices of anti-inflammatory and urate lowering drugs in gouty arthritis in the Province of Ontario. J Rheumatol 1988; 15: 1841–71

    PubMed  CAS  Google Scholar 

  93. Medellin MV, Erickson AR, Enzenauer RJ. Variability of treatment for gouty arthritis between rheumatologists and primary care physicians. J Clin Rheumatol 1997; 3: 24–7

    Article  PubMed  CAS  Google Scholar 

  94. Pawlotsky Y. What is the optimal treatment for acute crystal induced arthritis? Rev Rheum Engl Ed 1996; 63: 231–3

    CAS  Google Scholar 

  95. Wallace SL, Robinson H, Masi AT, et al. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895–900

    Article  PubMed  CAS  Google Scholar 

  96. Weinberger A, Pinkhas J. The efficacy of treatment with allopurinol versus uricosuric drugs in gout. Panminerva Med 1978 Jul–Sep; 20(3): 155–6

    PubMed  CAS  Google Scholar 

  97. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966; 64: 229–58

    PubMed  CAS  Google Scholar 

  98. Beutler AM, Rull M, Schlesinger N, et al. Treatment with allopurinol decreases the number of acute gout attacks despite persistently elevated serum uric acid [letter]. Clin Exp Rheumatol 2001; 19: 595

    PubMed  CAS  Google Scholar 

  99. Scott JT. Comparison of allopurinol to probenecid. Ann Rheum Dis 1966; 25: 623–6

    PubMed  CAS  Google Scholar 

  100. Altman A. Acute tumor lysis syndrome. Semin Oncol 2001; 28 (2 Suppl. 5): 3–8

    Article  PubMed  CAS  Google Scholar 

  101. Bomalaski JS, Clark MA. Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. Curr Rheumatol Rep 2004 Jun; 6(3): 240–7

    Article  PubMed  Google Scholar 

  102. Nishimura H, Matsushima A, Inada Y. Improved modification of yeast uricase with polyethylene glycol, accompanied with nonimmunoreactivity towards anti-uricase serum and high enzymic activity. Enzyme 1981; 26: 49–53

    PubMed  CAS  Google Scholar 

  103. Bomalaski JS, Holtsberg FW, Ensor CM, et al. Uricase formulated with polyethylene glycol (uricase-PEG 20): biochemical rationale and preclinical studies. J Rheumatol 2002 Sep; 29(9): 1942–9

    PubMed  CAS  Google Scholar 

  104. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Semin Arthritis Rheum 1998; 28: 48–59

    Article  PubMed  CAS  Google Scholar 

  105. Cohen A. Gout. Am J Med Sci 1936; 192: 448–93

    Article  Google Scholar 

  106. Yu TF, Gutman AB. Efficacy of colchicine prophylaxis in gout. Ann Intern Med 1961; 55: 179–92

    PubMed  CAS  Google Scholar 

  107. Yu TF. The efficacy of colchicine prophylaxis in articular gouta reappraisal after 20 years. Semin Arthritis Rheum 1982; 12: 258–64

    Article  Google Scholar 

Download references

Acknowledgements

The author has served on the Febuxostat National Advisory Board. No sources of funding were used to assist in the preparation of this review.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, One Robert Wood Johnson PL, PO Box 19, New Brunswick, New Jersey, USA

    Naomi Schlesinger

Authors
  1. Naomi Schlesinger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Naomi Schlesinger.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schlesinger, N. Management of Acute and Chronic Gouty Arthritis. Drugs 64, 2399–2416 (2004). https://doi.org/10.2165/00003495-200464210-00003

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200464210-00003

Keywords

Search

Navigation